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In spite of the availability of  effective chemotherapy and Bacille-Calmette -Guerin 
(BCG) vaccine, tuberculosis remains a leading infectious killer world-wide. Many 
factors such as, human immunodeficiency virus (HIV) co-infection, drug resistance, 
lack of patient compliance with chemotherapy, delay in diagnosis, variable efficacy of 
BCG vaccine and various other factors contribute to the mortality due to tuberculosis.  
In spite of the new advances in understanding the biology of Mycobacterium 
tuberculosis, and availability of functional genomic tools, such as microarray and 
proteomics, in combination with modern approaches, no new drug has been developed 
in the past 30 yr.  Therefore, there is an urgent need to identify new drug targets in 
mycobacteria and eventually, develop new drugs.  The release of the complete genome 
sequence of M. tuberculosis  has facilitated a more rational, and directional approach to 
search for new drug targets.  In general, gene products involved in mycobacterial 
metabolism, persistence, transcription, cell wall synthesis and virulence would be 
possible targets for the development of new drugs.  The exploitation of host cell 
signaling pathways for the benefit of the pathogen is a phenomenon that deserves to be 
looked into with a new perspective in the current scenario to combat M. tuberculosis .  
Reversible phosphorylation and dephosphorylation, which are carried out by specific 
protein kinases and phosphatases have been shown to modify the host proteins and 
help in the establishment of disease by several pathogenic bacteria.  In this review, we 
discuss some possible drug targets for M. tuberculosis . 
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Tuberculosis continues to be a major cause of morbidity and mortality throughout the world.  
Five decades of tuberculosis  control programmes using potentially efficacious drugs and the 
availability of BCG vaccine, have failed to reduce the prevalence of infection in most parts of the 
world.  It has been reported that more than 3 billion people have been vaccinated with BCG, but 
still TB kills more than 50,000 people every week and approximately one-third of the world 
population is asymptomatically infected by Mycobacterium tuberculosis1. It has been estimated 
that TB accounts for around 32 per cent deaths in HIV infected individuals2. The situation has 
exacerbated because of the presence of some complicating factors like, emergence of multidrug-
resistant TB3, HIV co-infection4 , lack of patient compliance with chemotherapy, and varia ble 
efficacy of Bacille -Calmette Guerin (BCG) vaccine.  A prerequisite for the effective control of 
tuberculosis is to understand the host-pathogen interactions and its contribution towards the 
development of disease.  Understanding host-pathogen interactions would give an important clue 
for developing new drugs, vaccine and diagnostic tests.  The release of complete genome 
sequence of M. tuberculosis has facilitated the development of more rational and specific 
methods to search for new drug targets and vaccine candidates. 
The success of mycobacteria in producing disease relies entirely on its ability to utilize 
macrophages for its replication and more importantly, the maintenance of viability of host 
macrophages that sustain mycobacteria. M. tuberculosis has evolved several mechanisms to 
circumvent the hostile environment of the macrophage, its primary host cell.  In spite of extensive 
research, our knowledge about the virulence factor(s) of M. tuberculosis is inadequate.  A variety 
of mechanisms have been suggested to contribute towards the survival of mycobacteria within 
macrophages.  These mechanisms include (i) inhibition of phagosome-lysosome fusion5;  (ii) 
inhibition of phagosome acidification6, (iii) recruitment and retention of tryptophan/aspartate 
containing coat protein on phagosomes to prevent their delivery to lysosomes7; and (iv) host-
induced expression of members of the PE-PGRS family of proteins8. 
The recent rise in TB cases and especially the increase of drug resistant mycobacteria indicate 
an urgent need to develop new anti-TB drugs.  The long duration of TB therapy is a consequence 
of persistent M. tuberculosis, not effectively killed by current anti-TB agents.  Recent advances in 
the knowledge of the biology of the organism and the availability of the genome sequence give an 
opportunity to explore a wide range of novel targets for drug design.  It is expected that the 
application of functional genomic tools, such as microarray and proteomics, in combination with 
modern approaches, such as structure-based drug design and combinatorial chemistry will lead to 
the development of new drugs that are not only active against drug resistant TB but can also 
shorten the chemotherapy schedule. 
Status of current tuberculosis drug therapy 
Drugs available for the treatment of tuberculosis can be classified into two categories; first line 
drugs such as, isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB) etc., and 
second line drugs like para amino salicylate (PAS), kanamycin, cycloserine (CS), ethionamide 
(ETA), amikacin, capreomycin, thiacetazone, fluoroquinolones etc . Current TB therapy, also 
known as DOTS (directly observed treatment, short-course) consists of an initial phase of 
treatment with 4 drugs, INH, RIF, PZA and EMB, for 2 months daily, followed by treatment with 
INH and RIF for another 4 months, three times a week9. The targets of these drugs are varied. 
INH, inhibits synthesis of mycolic acid, a cell well component10; PZA targets cell membrane 
whereas rifampin and streptomycin interferes with the initiation and streptomycin interferes with 
the initiation of RNA and protein synthesis respectively11. EMB blocks biosynthesis of 
arabinogalactan, a major polysaccharide present in the mycobacterial cell wall12 and kanamycin 
and capreomycin, like streptomycin, inhibit protein synthesis through modification of ribosomal 
structures at the 16S rRNA 13. Cycloserine prevents the synthesis of peptidoglycan, a constituent 
of cell wall14. 
Limitations of current drug therapy and need for new drug targets  
In the present scenario, due to the emergence of multi drug resistant tuberculosis (MDR-TB) 
and association between HIV and TB, DOTS is becoming rapidly ineffective in controlling 
tuberculosis.  Recent reports indicate that, areas where there is a high incidence of MDR-TB, 
DOTS is failing to control the disease15. In such circumstances, the second line  drugs are 
prescribed in combination with DOTS.  However, this combination of drugs is very expensive, 
has to be administered for a longer duration and has significant side effects.  One major drawback 
of current TB therapy is that the drugs are administered for at least 6 months. 
The length of therapy makes patient compliance difficult, and such patients become potent 
source of drug-resistant strains. The second major and serious problem of current therapy is that 
most of the TB drugs available today are ineffective against persistent bacilli, except for RIF and 
PZA.  RIF is active against both actively growing and slow metabolizing non-growing bacilli, 
whereas PZA is active against semi-dormant non-growing bacilli16. However, there are still 
persistent bacterial populations that are not killed by any of the available TB drugs.  Therefore, 
there is a need to design new drugs that are more active against slowly growing or non-growing 
persistent bacilli to treat the population at risk of developing active disease through reactivation.  
Secondly, it is important to achieve a shortened therapy schedule to encourage patient’s 
compliance and to slow down the development of drug resistance in mycobacteria. 
Impact of genome sequence on identification of new drug targets 
The complete genome sequence of M. tuberculosis17 provides an  opportunity  for a more 
focussed and planned approach towards the identification of new drug targets. Genome sequence 
helps in compilation of all the potential gene products encoded by a particular organism, 
identification of functions (enzymes and pathways) that are missing or unique in a particular 
organism, and finally identifying the genes that are common to all (or most) prokaryotes and 
eukaryotes.  An important advantage of this analysis is the possibility of identifying a novel target 
that is present in many bacteria and subsequently designing an antibiotic that could be active 
against a wide range of bacteria.  In addition, availability of human genome sequence can help in 
eliminating the potential drug targets that have close human homologues.  Thus, the possibility of 
using complete genome sequences for target identification are virtually unlimited. 
Possible drug targets 
In recent years, a number of new genes and their products in M. tuberculosis have been 
identified, which can be possible drug targets for tuberculosis. The gene products that control 
vital aspects of mycobacterial physiology like, metabolism, persistence, virulence, signal 
transduction and cell wall synthesis would be attractive targets for new drugs. 
A large number of genes are being studied in the search for new drug targets using various 
approaches.  Some  genes and their products reported in literature that can serve as drug target are 
discussed below. 
Genes involved in dormancy or persistence  
Mycobacteria has the unique property of becoming persistent or dormant for very long periods.  
This stage of mycobacteria poses a significant problem for effective therapy as these persistent 
bacilli are resistant to most of the currently available drugs for the treatment of  tuberculosis. The 
mechanism of mycobacterial persistence or dormancy is far from being understood.  Isocitrate 
lyase (ICL), a key enzyme of glyoxylate shunt has been shown to be involved in the persistence 
of M. tuberculosis in mice18. The interesting point is that ICL is not essential for the viability of 
tubercle bacilli in normal cultures or in hypoxic  conditions, but is important for persistence of 
bacilli in mice.  Recently, pcaA gene, which encodes a novel methyl transferase has also been 
shown to be involved in the persistence in mice.  This gene is involved in the modification of 
mycolic acids of mycobacterial cell wall.  The pcaA knockout strain of mycobacteria grew 
normally in vitro and replicated in mice similar to the wild type strain initially but was not able to 
persist19. Nevertheless, the role of icl and pcaA genes in the persistence of M. tuberculosis in vivo 
and the absence of homologous genes in the host make them good drug targets, which would 
potentially eliminate persistent bacilli in vivo. 
Genes involved in cell wall synthesis 
Mycobacteria including M. tuberculosis have a unique cell wall structure.  A variety of unique 
lipids like lipoarabinomannan (LAM), trehalose dimycolate, and phthiocerol dimycocerate which 
form non covalent anchorage with the cell membrane have been documented to play an important 
role in the virulence of M. tuberculosis20. Lipids such as cord factor have been suggested to play 
an important role in the virulence of M. tuberculosis by inducing cytokine mediated events21. 
LAM is also a major constituent of the mycobacterial cell wall and has been shown to induce 
TNF release from the macrophages22 which plays a significant role in bacterial killing.  
Because of the reasons cited above, genes involved in cell wall synthesis of mycobacteria have 
been exploited as targets for many anti-mycobacterial drugs.  Several important TB drugs such as 
INH, ETA and EMB target mycobacterial cell wall synthesis.  Enzymes involved in this pathway 
have always been preferred targets in drug development efforts.  For example, enzymes (RmlA to 
RmlD) which are involved in the synthesis of dTDP-rhamnose, an essential structural component 
of the cell wall of M. tuberculosis, have been selected for an in vitro screening with chemical 
library of 8,000 compounds23. 
Thiolactomycin (TLM) targets two b-ketoacyl-acyl-carrier protein synthases, KasA and KasB 
enzymes that belong to the fatty acid synthase type II system involved in the fatty acid and 
mycolic acid biosynthesis24. TLM has also been shown to be active against MDR-TB clinical 
isolate.  Several TLM derivatives have been found to be more potent in vitro against fatty acid 
and mycolic acid biosynthesis25. Cerulenin, an inhibitor of fatty acid synthesis, has also been 
shown to inhibit mycobacterial lipid synthesis and is active against M. tuberculosis in vitro with 
an MIC of 1.5-12.5 mg/ml26. Octanesulphonyl acetamide (OSA) has recently been identified as 
an inhibitor of fatty acid and mycolic acid biosynthesis in mycobacteria 27. The inhibitor was 
found to be active against both slow growers such as M. tuberculosis and also MDR-TB strains 
with a MIC of about 6.25-12.5 mg/ml.  Interestingly, OSA was found to be less active against fast 
growers such as M. smegmatis and M. fortuitum28. These reports clearly suggest that several 
genes of the cell wall synthesis pathway and enzymes involved in fatty acid and mycolic acid 
synthesis could be good candidates for further drug development. 
Virulence genes 
On the basis of the genome sequences of pathogens, using bioinformatics approach, a few 
genes have been proposed to play an important role in the virulence of mycobacteria.  In recent 
years, a number of techniques have been developed to delineate the differences between related 
pathogens and non-pathogens.  These techniques include PCR-based subtractive hybridization 
that can be used to specifically amplify DNA sequences that are present in one (e.g., virulent) but 
not in the other (e.g., avirulent) strain.  The other established method is signature tagged 
mutagenesis (STM), which provides a means for identific ation of genes which are important for 
bacteria to survive and proliferate in vivo. 
A number of genes have been identified, using different techniques like allelic exchange, 
signature tagged mutagenesis, and anti-sense RNA, that show a role in the virulence of M. 
tuberculosis. Some of these genes include, erp (extracellular repeat protein), which has been 
shown to be essential for the multiplication of mycobacteria during the acute phase of infection in 
the mouse model29.  The most important point is that this gene has no homologues in other 
organisms, making it an attractive drug target.  Recently, two gene clusters were identified and 
shown to be important for the growth of mycobacteria in the lungs during the early phase of 
infection.  This gene cluster is involved in the synthesis (fadD28) and export (mmpL7) of a 
complex cell wall associated lipid30 , phthiocerol dimycocerosate. 
The approach of targeting virulence factors, like other approaches suffers from some serious 
drawbacks, like virulence factors ma y not be necessarily survival genes.  Therefore, inhibition of 
virulence factors may not be lethal to the pathogen.  The other very important hurdle in this 
approach is that drugs that target virulence factors may be of very little or of no use if the disease 
has already been established.  However, inhibitors of these virulence gene products may be used 
in combination with existing drugs to improve the regime of chemotherapy31. 
Genes of signal transduction 
The exploitation of host cell signaling pathways for the benefit of the pathogen is a 
phenomenon that deserves to be looked into with a new perspective in the pathogenesis and drug 
target identification of   M. tuberculosis. Reversible phosphorylation and dephosphorylation is the 
key mechanism by which extracellular signals are translated into cellular responses.  These 
processes are carried out by specific protein kinases and phosphatases32.  It has been shown that, 
upon infection, the phosphatases and kinases of several pathogenic bacteria modify the host 
proteins that helps in the establishment of disease.  Phosphorylation generally takes places at 
histidine, serine, threonine or tyrosine residues.  Lipoarabinan (LAM) from the virulent species of 
M. tuberculosis has been shown to modulate host signaling pathways linked to bacterial survival 
by phosphorylation of an apoptotic protein (Bad) in phosphatidylinositol 3-kinase (PI-3K)-
dependent pathway in THP- 1 cells33. Earlier, it had been shown that a major anti-
phosphotyrosine reactive protein was present only in mycobacteria belonging to the M. 
tuberculosis complex34. 
Serine/threonine protein kinases: Serine and threonine kinases have been found to coordinate 
stress responses, developmental processes and pathogenicity in several microorganisms32. Serine/  
threonine kinase (YpkA) of Yersinia pseudotuberculosis helps in the virulence of pathogen by 
disrupting and reprogramming the host signaling network35. These kinases have also been 
suggested and control the late stages of development, sporulation or secondary metabolite 
production in bacteria 32.  Unlike Yersinia, Listeria monocytogenes invades mammalian cells and 
alters the host signaling by directly stimulating mitogen-activated protein (MAP) kinase upon 
attachment to epithelial cells36.  Another example of an active interaction between invasive 
bacteria and the host is provided by the human gastric epithelial pathogen Helicobacter pylori 
which induces cytoskeletal rearrangements following attachment to gastric cells, as well as 
inducing phosphorylation of two host protein37. 
The genome sequence of M. tuberculosis suggested the presence of eleven putative 
serine/threonine protein kinases17. Presence of these kinases, in such a large number in M. 
tuberculosis indicates a likely role for these proteins in the specific signal transduction events 
with host ligands.  It has been suggested that protein kinase G and F may change the 
phosphorylation pattern of host proteins upon infection, thereby, promoting the bacterial 
survival38.  Recently PknA has been shown to have a role in cell growth, division, and 
elongation39.  Moreover, kinase inhibitors, genistein, staurosporin and K252a have been shown to 
inhibit the development of few bacteria like, Myxococcus xanthus40.  Recently, it has been shown 
that an isoquinoline inhibitor reduces the growth of two mycobacterial species, M. smegmatis 
mc2 155 and M. bovis Bacille Calmette Guerin (BCG). This inhibitor also blocked the activity of 
PknB, a serine threonine kinase of M. tuberculosis in a dose dependent manner.  It has been 
speculated that this inhibitor may be active against other members of this family of kinases as 
well41. 
Tyrosine phosphatase : Pathogenic bacteria Yersinia pseudotuberculosis, secretes YopH, a 
tyrosine phosphatase in the host42 in order to down regulate  the cell signaling pathways of 
macrophages that are involved in phagocytosis43 and generation of the respiratory burst44.  
Similarly, another important intracellular pathogen, Salmonella typhimurium also secretes 
tyrosine phosphatase, SptP in the host through type III secretion system.  Secreted SptP binds and 
activates the intrinsic GTPase activity of GTP binding proteins Rac and Cdc42 leading to the 
disruption of host cytoskeletal network required for bacterial internalization45. 
The molecular basis of the pathogenicity of M. tuberculosis is far from being understood.  
However, both entry and subsequent survival of M. tuberculosis in the host cell appears to 
involve a specific cross talk between the host and pathogen.  This is validated by the fact that the 
uptake of M. tuberculosis by the macrophage is associated with a number of early signaling 
events such as recruitment and activation of Src family protein tyrosine kinases.  Recruitment of 
these proteins results in increased tyrosine phosphorylation of multiple macrophage proteins, and 
activation of phospholipase D(PLD)46.  Similarly, activation of protein tyrosine kinases appears 
to enhance stimulation of PLD activity and the associated increase in phosphatidic acid (PA).  It 
has been shown that increased phosphorylation may trigger a number of down stream processes 
necessary for membrane remodeling during phagocytosis and intracellular survival of M. 
smegmatis in the host cells47. It is known that M. tuberculosis has two functional secretary 
tyrosine phosphatases.  Moreover, of these two tyrosine phosphatases, one phosphatase MptpB is 
present exclusively in the members of M. tuberculosis complex suggesting that MptpB might play 
a role in the survival of mycobacteria. These phosphatases may dephosphorylate some of the host 
proteins which may be helpful in the invasion and establishment of disease48. 
Genes of two-component systems: Two-component systems (TCS) are vital components of signal 
transduction systems in a number of organisms.  It consists of a sensor kinase that senses external 
signals and transmits the signals to the response regulator. The response regulator interacts with 
transcription factors which in turn will switch on/off a number of genes49. 
It has been reported that disruption of a multitude of TCS in Streptococcus pneumoniae greatly 
reduced the ability of the pathogen to cause disease49. In addition, TCS have also been shown to 
be involved in the regulation of bacterial virulence in a number of organisms. The genome 
sequence of 
M. tuberculosis has shown the presence of at least 12 two-component system homologues with 8 
unlinked sensor kinases or response regulators17. However, the exact physiological role of most 
of these proteins is far from being understood.  It has been shown that the inactivation of mtrA 
component of mtrA-mtrB complex of M. tuberculosis H37Rv was possible only in the presence of 
a functional copy of mtrA, suggesting that this response regulator is essential for the viability of 
M. tuberculosis50. Interestingly, another two-component system, devR-devS, was found to be 
over expressed in a virulent strain, H37Rv51. Disruption of the phoP component of the 
PhoP/PhoR (TCS that controls transcription of virulence genes in a number of intracellular 
bacterial pathogens such as Salmonella, Shigella and Yersinia) in M. tuberculosis, resulted in a 
mutant strain with impaired multiplication in the host.  This mutant was also found to be 
attenuated in vivo in a mouse model52 , suggesting that PhoP  is required for intracellular growth of 
M. tuberculosis.  These observations collectively suggest that TCS in M. tuberculosis  could be  
important drug targets. 
Transcription factors  
Gene products that are involved in transcription regulation have long been used as target for 
drugs in a number of pathogens. For example rifampin, a well-known drug for tuberculosis, 
targets RNA polymerase.  The sigma factors have been shown to regulate gene expression in 
response to numerous environmental conditions in a number of bacterial species.  Genome 
sequence of M. tuberculosis revealed the presence of 13 sigma factors.  Sigma factors of 
mycobacteria like other bacteria also perform a multitude of functions.  Sigma factor RpoV (same 
as SigA) has been shown to be a virulence factor in M. bovis, as point mutation (arginine 522 to 
histidine) in RpoV has been shown to cause attenuation of virulence in a guinea pig model53.  It 
has been speculated that attenuation of virulence caused by the RpoV mutation might be due to 
the inability of the mutant RpoV to switch on certain virulence genes.  Besides the virulence 
genes, RpoV also controls many other housekeeping genes.  SigB has been shown to be induced 
during stationary phase54. Similarly, SigE is involved in heat stress, oxidative stress, stress due to 
exposure to SDS and survival in macrophages55.  Expression of both SigB and SigE is under the 
control of SigH 56.  Both SigE and SigH play a role in the resistance of M. smegmatis to various 
stress stimuli, including elevated temperature and oxidative stress. Moreover, expression of SigE 
and SigH of M. tuberculosis is markedly enhanced when the pathogen is inside the macrophages.  
Another sigma factor, SigF, has been shown to control the expression of Acr protein, which is 
induced in the macrophages and is necessary for the persistence of M. tuberculosis57. These 
observations clearly suggest that sigma factors especially the centrally important SigH, SigF and 
SigA are potential drug targets. 
Genes of other metabolic pathways  
Genes of some other metabolic pathways can also serve as possible targets for developing 
drugs against tuberculosis.  Some of these genes include, mgtc, which codes for a putative Mg+2 
transporter protein.  This protein has been shown to be essential for the survival of mycobacteria 
both, in macrophages and mice.  The D-mgtc mutant showed in vitro growth defects58. Similarly 
D-mbtB mutant deficient in synthesis of siderophores was unable to replicate within the 
macrophages.  Failure of mycobacteria to survive in the absence of specific iron uptake system 
suggests the scarcity of this important nutrient in phagosomal environment59. 
Members of PE-PGRS family of proteins that are highly expressed within tissue granulomas 
have been shown to be essential for the virulence of mycobacteria8. Therefore, the members of 
this category of genes also constitute potential drug targets. 
Conclusion 
Major obstacle in the cure and prevention of tuberculosis is posed by the latent or persistent 
M. tuberculosis infection.  This is due to the fact that most of the currently available drugs are 
ineffective against latent infection.  In spite of better understanding of the physiology of M. 
tuberculosis, our knowledge about the state of the bacillus during the latent period is far from 
being complete.  Moreover, a true representative model of latent tuberculosis in the laboratory 
setting is not available.  Establishment of such a system would certainly accelerate the efforts to 
understand the physiology of mycobacteria during the latent period and eventually it will help in 
the identification of new drug targets that can  act on the persistent mycobacteria.  Recent 
advances in modern biology, in combination with bioinformatic tools, proteomics and microarray 
technology would further facilitate the search of new drug targets agains t tuberculosis.  These 
exciting techniques are providing new avenues for understanding the biology of mycobacteria.  
The result of better understanding of the physiology of mycobacteria is manifested by the fact 
that the list of possible drug targets for tuberculosis is increasing day by day, the utility of these 
targets, however, cannot be predetermined. The list of potential drug targets encoded in the 
genome of   M.tuberculosis include genes involved in persistence or latency, cell wall synthesis, 
virulence, signal transduction, genes encoding transcription factors and enzymes of other 
intermediary metabolic pathways. All these targets should be explored to identify new drugs 
against tuberculosis that will overcome the limitations of existing drugs such as, prolonged 
chemotherapy, failure against persistent infection and multidrug resistance. 
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